Single B Cell Screening
Single B Cell Screening is a rapidly developing frontier technology in recent years for antibody drug development and immune response research. It involves isolating and analyzing individual B cells at the single-cell level to screen candidate cells that can produce high-affinity, highly specific antibodies. The basic principle of single B cell screening is to use flow cytometry or microfluidic platforms to isolate antigen-specific B cells expressing specific surface markers from the peripheral blood or lymphoid tissues of immune individuals (such as vaccinated individuals or disease recoverees). These cells are then subjected to single-cell RT-PCR to amplify the variable regions of their antibody heavy and light chain gene sequences, which are cloned and expressed as full-length antibodies. Functional screening quickly determines the affinity, neutralizing activity, or binding profile of these antibodies to the target, efficiently identifying candidate therapeutic antibodies. The advantage of single B cell screening lies in its ability to maintain the integrity of natural antibody pairing, avoiding the affinity loss or specificity shift that might occur with in vitro repairing, thus achieving a more natural balance between antibody affinity and biological function. In application, single B cell screening is widely used for neutralizing antibody screening in viral infections (such as influenza, Ebola, COVID-19), tumor-related antibody development in cancer immunotherapy, and the discovery and mechanistic research of specific antibodies in autoimmune diseases. The data not only aids in antibody development but also provides antigen epitope recognition insights for vaccine design, promoting the transition from empirical to structure-guided vaccine development. By integrating multi-omics data such as cancer genomics and proteomics, this screening technology can precisely identify tumor-infiltrating B cell populations within the tumor microenvironment, offering precise clues for developing personalized antibody immunotherapies.
Compared to traditional screening methods, single B cell screening has significant advantages in sensitivity and information depth. Traditional methods often require large library construction, prolonged screening cycles, and may overlook low-frequency but highly functional antibody clones, whereas single B cell screening can quickly locate high-quality antibodies from a small number of rare B cells with ideal functions. This is particularly important for discovering broad-spectrum neutralizing antibodies or individual-specific antibodies, especially during the early stages of emerging infectious disease outbreaks. This technology can quickly identify clinically potential antibody candidates from the blood samples of recoverees, significantly shortening the antibody drug development cycle.
The technical pathways of single B cell screening have gradually diversified. From the earliest antigen-labeled flow cytometry sorting to integrated platforms combining single-cell transcriptome sequencing and high-throughput antibody expression systems, the resolution and throughput of single B cell screening continue to improve. Researchers can also integrate it with high-throughput screening strategies to achieve rapid functional evaluation and structural optimization of antibody libraries. In the context of precision medicine, this technology is not limited to public antibody development but is widely used for tracking and analyzing individual immune responses. For example, by tracking the evolutionary trajectory of B cell clone profiles within the same patient over time, the persistence and diversity of immune responses can be deeply understood.
Although single B cell screening demands higher experimental complexity and data processing, its application in basic research and clinical development is rapidly expanding with the declining cost of single-cell sequencing and the proliferation of automated platforms. Modern single B cell screening not only seeks functional optimization of antibodies but also emphasizes sequence diversity and immunogenicity assessment, laying a solid foundation for subsequent humanization, affinity maturation, and CMC development.
Biotech Pack BioTech possesses a mature technical platform and extensive project experience, providing integrated solutions from sample collection, antigen-specific cell sorting, antibody gene cloning to functional validation. We support the screening of various antibody types (IgG, IgA, IgM, etc.) and utilize high-throughput sequencing and bioinformatics analysis for efficient antibody discovery and target analysis.
Biotech Pack BioTech - A premium service provider for bioproduct characterization and multi-omics mass spectrometry detection
Related Services:
How to order?






